Cargando…

MODL-04. Drug screening in Disorders with Abnormal DNA Damage Response/Repair (DADDR) andin vivo validation

INTRODUCTION: Disorders with Abnormal DNA Damage Response/Repair (DADDRs) are inherited conditions caused by constitutional mutations of DNA damage response and repair genes and are characterized by an increased cancer risk. Furthermore, affected individuals also show an elevated risk of secondary n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kolodziejczak, Anna, Selt, Florian, Peterziel, Heike, Jamaladdin, Nora, Mack, Norman, Maass, Kendra, Kool, Marcel, Herold-Mende, Christel, El Damaty, Ahmed, Oehme, Ina, Jones, David T W, Witt, Olaf, Pajtler, Kristian W, Kratz, Christian, Pfister, Stefan M, Milde, Till
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Preclinical Models/Experimental Therapy/Drug Discovery
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164948/ http://dx.doi.org/10.1093/neuonc/noac079.627

Ejemplares similares

MODL-01. Targeting replication stress in pediatric brain tumors
por: Krausert, Sonja, et al.
Publicado: (2022)

MODL-02. TARGETING REPLICATION STRESS IN PEDIATRIC BRAIN TUMORS
por: Krausert, Sonja, et al.
Publicado: (2020)

MODL-04. MODELING CNS HGNET-BCOR PATHOGENESIS USING NEURAL STEM CELLS
por: Nakata, Satoshi, et al.
Publicado: (2020)

MODL-07. DNA methylation-based biobank of murine models for pediatric tumors
por: Zheng, Tuyu, et al.
Publicado: (2022)

MODL-11. COMPARISON OF HUMAN & MURINE PA/PXA CHARACTERISTICS
por: Sommerkamp, Alexander C, et al.
Publicado: (2020)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

MODL-06. PRECLINICAL EFFICACY OF THE IMIPRIDONE ONC-206 AGAINST MEDULLOBLASTOMA
por: Malhotra, Anshu, et al.
Publicado: (2020)

MODL-30. DISSECTING THE ROLE OF MULTI-CILIOGENESIS NETWORK IN CHOROID PLEXUS TUMOR
por: Zhao, Haotian, et al.
Publicado: (2020)

MODL-06. Targeting c-MET in combination with radiation is effective in MET-fusion driven high-grade glioma
por: Zuckermann, Marc, et al.
Publicado: (2022)

MODL-03. ADAPTING PALBOCICLIB FOR MEDULLOBLASTOMA THERAPY BY IMPROVING DRUG DELIVERY AND ADDRESSING RESISTANCE
por: Dismuke, Taylor, et al.
Publicado: (2020)

MODL-08. OPTIMIZATION OF A NOVEL LOCAL DELIVERY SYSTEM FOR THE TREATMENTS OF SUPRATENTORIAL EPENDYMOMA
por: Ruff, Lisa, et al.
Publicado: (2020)

MODL-13. GENETICALLY ENGINEERED PIG MODEL OF RHABDOID TUMOR PREDISPOSITION SYNDROME-1
por: Na, Brian, et al.
Publicado: (2020)

MODL-15. THE COMBINATION TREATMENT OF PARP INHIBITOR AND TMZ, OR DAG WILL BE PROMISING TREATMENT IN SF8628
por: Ohba, Shigeo, et al.
Publicado: (2020)

MODL-21. INTEGRATIVE APPROACHES IN FUNCTIONAL GENOMICS TO IDENTIFY GENETIC DEPENDENCIES IN PEDIATRIC BRAIN CANCER
por: Sun, Claire, et al.
Publicado: (2020)

MODL-28. IMMUNE PRIMING WITH INTERFERON-Γ COMBINED WITH EPIGENETIC MODULATION IN PEDIATRIC BRAIN TUMORS
por: Crotty, Erin, et al.
Publicado: (2020)

MODL-26. CHILDREN’S BRAIN TUMOR NETWORK: ACCELERATING RESEARCH THROUGH COLLABORATION AND OPEN-SCIENCE
por: Lilly, Jena, et al.
Publicado: (2020)

MODL-12. DEVELOPMENT OF A NOVEL IMMUNOCOMPETENT MOUSE MODEL FOR DIFFUSE INTRINSIC PONTINE GLIOMA
por: Seblani, Maggie, et al.
Publicado: (2020)

MODL-29. EVALUATING TUMOR-IMMUNE INTERACTIONS IN MOUSE MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA
por: Furnish, Robin, et al.
Publicado: (2020)

MODL-14. SMALL MOLECULE TARGETING OF ONCOGENIC FGF2-FGFR SIGNALING IN BRAIN TUMORS
por: Kumar, Karthiga Santhana, et al.
Publicado: (2020)

MODL-28. Patient-derived, three-dimensional organoid platform for pediatric brain tumor modeling
por: Baubet, Valerie, et al.
Publicado: (2022)

MODL-03. Establishment of intraventricular Shh inhibition as a therapeutic option for young patients with medulloblastoma
por: Kresbach, Catena, et al.
Publicado: (2022)

MODL-02. A novelCre-conditionalcMYC-driven MB Group 3 transgenic mouse model shows traceable leptomeningeal dissemination.
por: Morcavallo, Alaide, et al.
Publicado: (2022)

MODL-22. DEVELOPING A REAL-TIME PERSONALIZED DRUG TESTING PLATFORM FOR PEDIATRIC CNS CANCERS
por: Laternser, Sandra, et al.
Publicado: (2020)

MODL-05 Metronomic Intrathecal Delivery of CDK4/6 Inhibitors in Preclinical Models of Pediatric Brain Tumors
por: Guadix, Sergio, et al.
Publicado: (2022)

MODL-23. DNA METHYLATION AND COPY NUMBER VARIATION PROFILE FOR CHARACTERIZATION OF PEDIATRIC BRAIN TUMOR PRIMARY CELL LINES
por: Pedace, Lucia, et al.
Publicado: (2020)

MODL-24. AN ORGANOTYPIC CHUNK CULTURE TECHNIQUE TO STUDY DISEASE MECHANISM AND DEVELOP TARGETED THERAPEUTICS FOR PEDIATRIC ADAMANTINOMATOUS CRANIOPHARYNGIOMA
por: Vijmasi, Trinka, et al.
Publicado: (2020)

Géodynamique andine : résumés des communications
Publicado: (1990)

MODL-27. MEK INHIBITION WITH TRAMETINIB SLOWS PROGRESSION OF MEDULLOBLASTOMA AND ATYPICAL TERATOID RHABDOID TUMOR IN ORTHOTOPIC XENOGRAFT MURINE MODEL
por: Mushrif, Sujata, et al.
Publicado: (2020)

MODL-19. DIPG HARBOUR ALTERATIONS TARGETABLE BY MEK INHIBITORS, WITH ACQUIRED RESISTANCE MECHANISMS OVERCOME BY COMBINATORIAL UP- OR DOWN-STREAM INHIBITION
por: Izquierdo, Elisa, et al.
Publicado: (2020)

MODL-16. ABEMACICLIB, A SELECTIVE CDK4/6 INHIBITOR, RESTRICTS GROWTH OF PEDIATRIC GLIAL-LINEAGE TUMORS IN VITRO AND IN VIVO
por: Liang, Muh-Lii, et al.
Publicado: (2020)

MODL-25. REPLICATION REPAIR DEFICIENT MOUSE MODELS PROVIDE INSIGHT ON HYPERMUTANT BRAIN TUMOURS, MECHANISMS OF IMMUNE EVASION, AND COMBINATORIAL IMMUNOTHERAPY
por: Galati, Melissa, et al.
Publicado: (2020)

MODL-31. Novel in vivo models of post-radiation recurrent pediatric high-grade glioma show increased susceptibility to MAPK inhibition
por: Knox, Aaron, et al.
Publicado: (2022)

MODL-09. FEASIBILITY OF ACUTE SLICE CULTURE-SINGLE CELL SEQUENCING DRUG SCREENING AS A TOOL TO SELECT THERAPY FOR CHILDREN WITH RELAPSED BRAIN TUMORS
por: Gampel, Bradley, et al.
Publicado: (2020)

MODL-31. RADIATION-DERIVED TREATMENT-RESISTANT PDX AND CELL CULTURE MODELS RECAPITULATE THE CHARACTERISTICS OF MATCHED PRIMARY/RECURRENT PEDIATRIC HIGH-GRADE GLIOMA
por: Knox, Aaron J, et al.
Publicado: (2020)

MODL-20. A BIOBANK OF ~100 PATIENT-DERIVED MODELS REPRESENTING BIOLOGICAL HETEROGENEITY AND DISTINCT THERAPEUTIC DEPENDENCIES IN PAEDIATRIC HIGH GRADE GLIOMA AND DIPG
por: Carvalho, Diana, et al.
Publicado: (2020)

MODL-27. An organotypic brain slice culture platform as a novel pre-clinical model for diffuse intrinsic pontine glioma and diffuse midline glioma
por: Mann, Breanna, et al.
Publicado: (2022)

MODL-30. Children’s Brain Tumor Network preclinical tumor models development and sharing platform: collaborative model empowering pediatric brain tumor discovery and global research.
por: Koptyra, Mateusz, et al.
Publicado: (2022)

MODL-17. SHP2 INHIBITORS SHOW ACTIVITY AGAINST NF1-DEFICIENT GLIOMAS AND ENHANCE MAPK PATHWAY INHIBITION IN BRAF-V600E MUTANT GLIOMAS
por: Muldoon, Daniel, et al.
Publicado: (2020)

LGG-16. NOVEL COMBINATION THERAPIES FOR PEDIATRIC LOW-GRADE GLIOMA AND CHARACTERIZATION OF THE UNDERLYING CELL DEATH MECHANISMS
por: Zeiser, Constantia, et al.
Publicado: (2023)

Class I HDAC inhibition reduces DNA damage repair capacity of MYC-amplified medulloblastoma cells
por: Vollmer, Johanna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_stcpnr5t6tq8dfhvvi9k2v5fr7